Vrati se na sadržaj

Bolest srpastih ćelija (pedijatrija)

Lečenje anemije

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (otvara novi prozor)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Izvor‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indeks‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (otvara novi prozor)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (otvara novi prozor)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Izvor‎: Acta Haematol 1995;94(3):128-34.

Indeks‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (otvara novi prozor)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (otvara novi prozor)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Izvor‎: Haematologica 2006;91(8):1076-83.

Indeks‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (otvara novi prozor)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (otvara novi prozor)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Izvor‎: J Obstet Gynaecol 2007;27(1):82-3.

Indeks‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (otvara novi prozor)